Vandortuzumab vedotin

Cat. No. M24699

All AbMole products are for research use only, cannot be used for human consumption.

Synonym:

DSTP 3086S; RG 7450; MSTP2109A

Size	Price	Availability
100ug	USD 600 USD600	1-2 Weeks
1mg	USD 1200 USD1200	1-2 Weeks

Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation

Purity:
COA
MSDS

Product Information

Biological Activity

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

Chemical Information

CAS Number	1471985-92-8
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Anthony Markham. Drugs. Tisotumab Vedotin: First Approval

[2] Emma D Deeks. Drugs. Disitamab Vedotin: First Approval

[3] Emma D Deeks. Drugs. Polatuzumab Vedotin: First Global Approval

[4] Carrie Van Der Weyden, et al. Expert Rev Hematol. Brentuximab vedotin in T-cell lymphoma

[5] Craig H Moskowitz, et al. Lancet. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Catalog

Keywords: Vandortuzumab vedotin, DSTP 3086S; RG 7450; MSTP2109A supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.

By Signaling Pathways

By Product Type

Signaling Pathways

Vandortuzumab vedotin

DSTP 3086S; RG 7450; MSTP2109A

Quality Control & Documentation

Biological Activity

Chemical Information

References

Get to Know Us

Customer Support

Resources

Contact Us